SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into SAB Biotherapeutics, Inc.
- NEW YORK, NY / ACCESSWIRE / October 3, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
- 10/03/2024
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into SAB Biotherapeutics, Inc.
- NEW YORK, NY / ACCESSWIRE / September 30, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
- 09/30/2024
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into SAB Biotherapeutics
- NEW YORK, NY / ACCESSWIRE / September 27, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
- 09/27/2024
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into SAB Biotherapeutics, Inc.
- NEW YORK, NY / ACCESSWIRE / September 27, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
- 09/27/2024
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into SAB Biotherapeutics
- NEW YORK, NY / ACCESSWIRE / September 27, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
- 09/27/2024
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into SAB Biotherapeutics, Inc.
- NEW YORK, NY / ACCESSWIRE / September 24, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
- 09/24/2024
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into SAB Biotherapeutics, Inc.
- NEW YORK, NY / ACCESSWIRE / September 23, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
- 09/23/2024
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into SAB Biotherapeu
- NEW YORK, NY / ACCESSWIRE / September 20, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
- 09/20/2024
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into SAB Biotherapeutics, Inc.
- NEW YORK, NY / ACCESSWIRE / September 19, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
- 09/19/2024
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into SAB Biotherap
- NEW YORK, NY / ACCESSWIRE / September 18, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
- 09/18/2024
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into SAB Biotherap
- NEW YORK, NY / ACCESSWIRE / September 16, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
- 09/17/2024
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into SAB Biotherapeutics, Inc.
- NEW YORK, NY / ACCESSWIRE / September 13, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
- 09/13/2024
|
SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference
- MIAMI, Sept. 13, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of T1D, today announced that Chairman and CEO Samuel J. Reich will be participating in a fireside chat at the 2024 Cantor Global Healthcare Conference, September 17-19th, 2024.
- 09/13/2024
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into SAB Biotherap
- NEW YORK, NY / ACCESSWIRE / September 11, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
- 09/12/2024
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into SAB Biotherapeu
- NEW YORK, NY / ACCESSWIRE / September 10, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
- 09/10/2024
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into SAB Biotherapeutics, Inc
- NEW YORK, NY / ACCESSWIRE / September 9, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
- 09/09/2024
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into SAB Biotherapeupeutics, Inc.
- NEW YORK, NY / ACCESSWIRE / September 6, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
- 09/06/2024
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into SAB Biotherap
- NEW YORK, NY / ACCESSWIRE / September 5, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
- 09/05/2024
|
SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting
- MIAMI, Sept. 04, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that it will present at the European Association for the Study of Diabetes 60th Annual Meeting on September 9, 2024 in Madrid. SAB's Executive Vice President and Chief Medical Officer Alexandra Kropotova, MD, MBA will present “Protecting pancreatic beta cells with multi-target, multi-epitope immunotherapy: SAB-142.”
- 09/04/2024
|
SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates
- FDA provided clearance to SAB's IND Appointed Lucy To as Chief Financial Officer Announced founding of a new Clinical Advisory Board MIAMI, Aug. 08, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today reported financial results for the second quarter ended June 30, 2024, and provided a company update. “We've had a strong quarter as we drive closer to our upcoming SAB-142 milestones.
- 08/08/2024
|
SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes
- MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced the founding of a clinical advisory board to provide expert insight and guidance to the Company in the clinical development of SAB-142, its leading therapeutic candidate.
- 08/05/2024
|
SAb Biotherapeutics Rebrands as SAB BIO
- New name, logo and website updates, stock symbol will remain SABS With new brand identity, SAB BIO continues drive towards serious unmet needs in type 1 diabetes MIAMI, June 20, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced its new name, SAB BIO, and visual identity to more closely align with its mission to treat and prevent immune and autoimmune disorders with the use of its unique immunotherapy platform. This rebrand includes a new name, logo mark and website updates to reflect the company's strategic evolution.
- 06/20/2024
|
SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions
- MIAMI, June 18, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that it will present a poster at the ADA 84th Scientific Sessions on June 21-24, 2024 in Orlando, Florida. The poster will be presented by SAB's Senior Program Manager, Eric Sandhurst, Ph.D, and published online in the journal Diabetes®.
- 06/18/2024
|
SAB Biotherapeutics Announces Departure of Chief Financial Officer
- MIAMI, May 30, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of T1D, today announced that effective June 4, its Chief Financial Officer Michael King will be departing the company to accept a role as CEO at a privately-held oncology company. He will continue as an advisor to SAB through the end of the year.
- 05/30/2024
|
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
- MIAMI, May 21, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), today announced that the U.S. Food and Drug Administration (FDA) has provided clearance for the Company's investigational new drug (IND) application to proceed for its phase 1 clinical trial for type 1 diabetes (T1D) therapy SAB-142. SAB is a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of T1D.
- 05/21/2024
|
SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates
- MIAMI, May 20, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today reported financial results for the first quarter ended March 31, 2024, and provided a company update. “As we work towards upcoming SAB-142 milestones, I remain enthusiastic about our ongoing progress executing a focused corporate strategy centered on immunotherapy, T1D,” notes SAB chairman and CEO Samuel J.
- 05/20/2024
|
SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors
- MIAMI, May 06, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that Jay Skyler, MD, MACP, FRCP has been appointed to the company's Board of Directors.
- 05/06/2024
|
SAB Biotherapeutics Provides SAB-142 Trial Update
- MIAMI BEACH, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced their Chief Medical Officer, Dr. Alexandra Kropotova, MD, MBA disclosed that SAB has completed dosing the third cohort for SAB-142 with no observation of serum sickness thus far.
- 04/16/2024
|
SAB Biotherapeutics to Present at INNODIA Annual Meeting
- MIAMI BEACH, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced their Chief Medical Officer, Dr. Alexandra Kropotova, MD, MBA will share an overview of the SAB-142 clinical development plan and anticipated milestones at the INNODIA Annual Meeting in Leuven, Belgium on April 11, 2024.
- 04/08/2024
|
SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference
- Miami, FL , April 04, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced Samuel J. Reich, the company's Chairman and CEO, will present an overview of the company at the upcoming 23rd Annual Needham Virtual Conference on Thursday, April 11, 2024 at 1:30 p.m. ET.
- 04/04/2024
|
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results
- Sioux Falls, SD , March 29, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results March 29, 2024 SAB-142 Phase 1 trial on track for data release during 2024 Completed financing for up to $110 million with leading life science investors Cash and equivalents of $56.6 million as of December 31, 2023 Company expects its cash and equivalents, with exercise of Tranche B warrants, will fund operations into 2026 Sioux Falls, SD March 29, 2024 (GlobeNewswire)—SAB Biotherapeutics, Inc. (Nasdaq:SABS), (“SAB” or “the company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of Type 1 diabetes (T1D), today announced its financial results for the fourth quarter of 2023 in addition to its full year financial results for the fiscal year ended December 31, 2023, and reported on recent accomplishments and expected upcoming milestones. “During 2023, we significantly changed the direction of our company to focus on SAB-142, our innovative, human anti-thymocyte immune globulin for the prevention of progression of T1D” stated Samuel J.
- 03/29/2024
|
SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment
- SIOUX FALLS, S.D., March 25, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that the Navy Medical Research Command (NMRC) is moving forward with a safety and tolerability study to evaluate SAB-176, a therapy being investigated for use as a pre- and post-exposure prophylactic treatment for influenza type A and type B, pursuant to the Cooperative Research and Development Agreement that governs the relationship between SAB and the NMRC.
- 03/25/2024
|
SAB Biotherapeutics to Present at the BIO CEO & Investor Conference
- SIOUX FALLS, S.D., Feb. 23, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced Samuel J. Reich, the Company's Chairman and CEO, will present an overview of the Company at the BIO CEO & Investor Conference on Monday, February 26, 2024 at 3:15 PM EST.
- 02/23/2024
|
SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- SIOUX FALLS, S.D., Feb. 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced Samuel J. Reich, the Company's Chairman and CEO, will present an overview of the Company at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024 at 1:20 PM EST.
- 02/08/2024
|
SAB Biotherapeutics Announces Executive Leadership Change
- SIOUX FALLS, S.D., Feb. 02, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced Samuel J. Reich, currently the Executive Chairman of SAB, will expand his role to include that of Chief Executive Officer of SAB, effective February 2, 2024.
- 02/02/2024
|
SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
- SIOUX FALLS, S.D., Jan. 23, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics , Inc. (Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that it received notice from The Nasdaq Stock Market LLC ("Nasdaq") on January 23, 2024 informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule") for continued listing on the Nasdaq Capital Market.
- 01/23/2024
|
SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
- SIOUX FALLS, S.D., Jan. 02, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a fully-human anti-thymocyte immunoglobulin (hIgG) for disease-modification of Type 1 Diabetes (T1D), today announced that it will effect a reverse stock split of its outstanding shares of common stock, effective as of 12:01 a.m. Eastern Time on January 5, 2024.
- 01/02/2024
|
Here's Why SAB Biotherapeutics, Inc. (SABS) Is a Great 'Buy the Bottom' Stock Now
- SAB Biotherapeutics, Inc. (SABS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
- 12/08/2023
|
SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes
- First subject has been dosed in the first-in-man Phase 1 clinical study of SAB-142, the first fully-human anti-thymocyte immunoglobulin (ATG)
- 11/29/2023
|
SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors
- SIOUX FALLS, S.D., Nov. 20, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing a fully-human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that Katie Ellias has been appointed to the Company's Board of Directors.
- 11/20/2023
|
SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes
- SIOUX FALLS, S.D., Nov. 14, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ: SABS), a clinical stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for delaying the onset of progression of type 1 diabetes (T1D), today announced the funding of the second tranche of a previously-announced financing, raising total aggregate proceeds to date of $67.1 million. The proceeds from the financing will be used to fund the development of the company's lead research program, SAB-142, a potential disease modifying treatment for T1D.
- 11/14/2023
|
SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates
- Raises combined $67.1M in private placement plus Tranche warrant exercise with syndicate of leading investors
- 11/14/2023
|
SAB Biotherapeutics to Present at Piper Sandler Healthcare Conference
- SIOUX FALLS, S.D., Nov. 09, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics , Inc. (Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that Eddie J. Sullivan, Ph.D., co-founder, President and Chief Executive Officer of SAB Biotherapeutics will present at the 35th Annual Piper Sandler Healthcare Conference, taking place from November 28 to November 30, 2023 at The Lotte New York Palace in New York.
- 11/09/2023
|
SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer
- Finance leader joins SAB with more than 25 years of experience as a leading biotech equity research analyst Finance leader joins SAB with more than 25 years of experience as a leading biotech equity research analyst
- 10/24/2023
|
SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes
- Australian Human Research Ethics Committee (HREC) grants approval for SAB to begin first-in-human Phase 1 clinical study of SAB-142, the first fully human anti-thymocyte immunoglobulin (ATG)
- 10/19/2023
|
SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of Directors
- SAB also announces closing of $7.5 million financing, the first tranche of $130 million private placement SAB also announces closing of $7.5 million financing, the first tranche of $130 million private placement
- 10/05/2023
|
SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International Convention
- SAB Biotherapeutics President & Chief Executive Officer Eddie Sullivan, Ph.D. to present novel DiversitAb™ platform pipeline, with emphasis on partnering influenza therapeutic, SAB-176 SAB Biotherapeutics President & Chief Executive Officer Eddie Sullivan, Ph.D. to present novel DiversitAb™ platform pipeline, with emphasis on partnering influenza therapeutic, SAB-176
- 05/30/2023
|
SAB Biotherapeutics to Present at Sidoti Virtual Investor Conference, May 10-11
- SIOUX FALLS, S.D., May 03, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human, multi-epitope binding immunoglobulin IgG1 (polyclonal) antibodies without the need for human donors, is pleased to announce that Eddie Sullivan, PhD, co-founder, President & CEO of SAB Biotherapeutics, will be presenting and hosting one-on-one meetings with investors at the upcoming Sidoti Virtual Investor Conference on May 10 at 11:30am ET. The presentation can be accessed live at: https://sidoti.zoom.us/webinar/register/WN_hky73f7PSt6rJa3TODNaAQ.
- 05/03/2023
|
Promising Upsides on these Biotech Penny Stocks
- For investors willing to do their research and take calculated risks, biotech penny stocks can offer the potential for high returns. These companies have a low market capitalization and are not yet profitable, but they offer the potential for high growth as their products gain regulatory approval and market acceptance.
- 04/18/2023
|
SAB Biotherapeutics up 80% after FDA grants fast-track status to flu therapeutic
- SAB Biotherapeutics (NASDAQ:SABS) announced on Thursday that the US Food and Drug Administration (FDA) has granted Fast Track designation for its investigational therapeutic SAB-176 for Type A and Type B influenza illness in high-risk patients, including those who have anti-viral resistant strains, causing the company's shares to shoot up more than 80%. A Fast Track designation allows drugmakers to expedite the development and review of medicines that target critical illnesses and address unmet medical needs.
- 04/13/2023
|
SAB Biotherapeutics CMO Selected to Present at the January 2023 Biotech Showcase in San Francisco
- SIOUX FALLS, S.D., Dec. 15, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, high-avidity, fully-human polyclonal antibodies without the need for human donors, announced today that SAB Biotherapeutics has been selected to present at the Biotech Showcase 2023 meeting, an investor conference that drives biotech innovation and global collaboration through presentations delivered by innovative biotech companies, face-to-face networking and one-to-one meetings. The conference is taking place Jan. 9-11 in San Francisco, in parallel with the J.P. Morgan 41st Annual Health Care Conference.
- 12/15/2022
|
SAB (SABS) Abandons COVID-19 Treatment Study, Stock Plummets
- Low hospitalization rates force SAB Biotherapeutics (SABS) to discontinue the late-stage study that is evaluating its COVID-19 antibody treatment. Stock down almost 40% post the announcement.
- 03/03/2022
|
SAB Biotherapeutics (SABS) Posts Data From COVID Treatment Study
- Following positive data from phase II study, SAB Biotherapeutics (SABS) starts a phase III study evaluating its COVID antibody treatment.
- 01/26/2022
|
On Positive Virology Data, SAB Biotherapeutics' COVID-19 Drug To Move To Phase 3 In NIH ACTIV-2 Trial
- SAB Biotherapeutics Inc (NASDAQ: SABS) has reported positive Phase 2 safety and efficacy data demonstrating that SAB-185 met the criteria required to move to Phase 3 in the National Institutes of Health (NIH) COVID-19 ACTIV-2 Trial. SAB-185 is a fully human, specifically targeted, broadly neutralizing polyclonal antibody candidate for high-risk non-hospitalized patients with mild to moderate COVID-19.
- 01/24/2022
|
FDA Lab Testing Confirms SAB Biotherapeutics' COVID-19 Antibody Neutralizes Omicron Variant
- SAB Biotherapeutics Inc (NASDAQ: SABS) announced that SAB-185, its COVID-19 therapeutic candidate, retains neutralization activity against the omicron variant in an in vitro pseudovirus model. The results indicate that SAB-185 retains a potent ability to neutralize recombinant S protein lentiviral pseudovirus that mimics the SARS-CoV-2 Omicron (B.1.1.529) variant.
- 12/16/2021
|
SAB Biotherapeutics' Influenza Candidate Achieves Primary Goal In Mid-Stage Study
- SAB Biotherapeutics Inc (NASDAQ: SABS) has announced data from a Phase 2a challenge study of SAB-176, its investigational therapy for treating seasonal influenza. SAB-176 is a quadrivalent fully human polyclonal antibody therapeutic candidate designed to treat moderate to severe Type A and B seasonal influenza viruses.
- 12/01/2021
|
